Shares of Mirati Therapeutics Inc. MRTX, -1.96% jumped 6.0% in premarket trading on Thursday after the company said the Food and Drug Administration granted a breakthrough therapy designation to Krazati as a treatment for colorectal cancer. The drug is already approved to treat certain kinds of non-small cell lung cancer. Mirati’s stock has tumbled 71.8% so far this year, while the broader S&P 500 SPX, +0.59% is down 18.6%.
This article was originally published by Marketwatch.com. Read the original article here.
